Predictors of good clinical response (BASDAI 50 or ASAS partial remission) in 1,250 patients treated with adalimumab (humira (R)) for active ankylosing spondylitis (AS) за авторством Rudwaleit, M, Claudepierre, P, Wordsworth, P, Loza, E, Wong, R, Kron, M, Kary, S, Kupper, H

IN PATIENTS WITH ANKYLOSING SPONDYLITIS (AS), ADALIMUMAB IMPROVES INFLAMMATORY BOWEL DISEASE (IBD) AND PSORIASIS (Ps) AND PREVENTS ANTERIOR UVEITIS (AU) FLARES за авторством Wordsworth, P, Rudwaleit, M, Claudepierre, P, Loza, E, Olivieri, I, Wong, R, Oezer, U, Kary, S, Kupper, H

Adalimumab (HUMIRA (R)) improves inflammatory bowel disease (IBD) and psoriasis (Ps) and prevents anterior uveitis (AU) flares in patients with Ankylosing spondylitis (AS) за авторством Rudwaleit, M, Claudepierre, P, Loza, E, Wordsworth, P, Olivieri, I, Wong, R, Oezer, U, Kary, S, Kupper, H

Adalimumab is effective and well-tolerated in patients with ankylosing spondylitis (AS) in day-to-day clinical practice - Results from rhapsody за авторством Wordsworth, P, Claudepierre, P, Loza, E, Olivieri, I, Keat, A, Mantika, I, Wong, R, Kron, M, Kupper, H, Rudwaleit, M